Your Cart
Customer Service
We Value Privacy
Your Security
Our Guarantee
Shipping & Freight
Terms & Conditions
Your Order Questions
Visit Online Store
FREE Newsletter
Subscribe for FREE to Epismooth News and receive skin tips, expert articles, special deals and much more.
FREE Report
Subscribe to the Epismooth.com FREE Report detailing the latest and greatest in psoriasis and eczema care. Don't miss out, enter your email address below to subscribe!
Your online shopping experience with Epismooth.com is fully secured by Verisign.
Search
Enter search term:
Testimonials
"Within a week of using Calendulis Plus Cream, my eczema had diminished considerably and the unbearable itch had ceased!"
Chelsea,
Vic, Australia
Tip Of The Week
Remember water is the best drink when you have eczema. Avoid flavors, colorings or preservatives, as these are prone to trigger eczema.
Become An
Affiliate
Would you like to help others find expert advice and top quality products for eczema and psoriasis?
And make extra cash by becoming an affiliate?
We Accept: 
BioCryst
We are forever hearing of new drugs being developed to treat the chronic inflammatory skin condition psoriasis.
Birmingham based BioCryst Pharmaceuticals Inc has successfully completed phase 1 trials of its new psoriasis drug BCX-4208 and plans to start the second phase later this year.
The first phase, a single oral dose, was well tolerated among participants when safety guidelines were strictly enforced. The drug is intended to block key enzymes involved in autoimmune diseases where T-cell activation is involved.
BioCryst intends to investigate the potential of BCX-4208 for the treatment of other autoimmune conditions like rheumatoid arthritis, Crohns disease as well as organ transplant rejection.
“The results from our first trial are very encouraging, and we are committed to the development of BCX-4208 for the treatment of psoriasis and other T-cell medicated conditions where an oral therapy offers clear advantages and might greatly improve patient quality of life,” Dr. Charles E. Bugg, BioCryst’s chairman and chief executive, said in a written statement.
Mel Sinclair, RN